|
Trial Name |
Description of Trial |
|
PRESTO |
Prevention of restenosis by tranilast and its outcomes. |
| PROSE | Thromboembolic complications - randomized trial of previous and current generation mechanical prostheses. |
|
PROTECT |
Prospective
re-infarction outcomes in the thrombolytic era cardizem |
| PROTECT ARMS |
Preventing radial occlusion through more effective closure therapy and advanced radial management study. |
QUASAR |
The efficacy of quinapril in patients with coronary artery disease, silent ischemia, and effort-induced angina. |
QUARK |
A randomized, double-blind, placebo controlled, phase 3 study to evaluate the efficacy and safety of QPI-1002 for the prevention of major adverse kidney events (MAKE) in subjects at high risk for acute kidney injury (AKI) following cardiac surgery. |
| RAPID ACS | Radial PCI - day procedure for non-ST elevation acute coronary syndromes. |
|
RANOLAZINE CVT 3031 |
A double-blind, placebo-controlled, 4-period cross-over, multiple dose study of ranolazine SR as monotherapy for chronic stable angina pectoris at doses of 500 mg bid, 100 mg bid and 1500 mg bid. |
| RE-COVER |
Oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. |
| RE-COVER II |
Oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parental anticoagulant approved for this indication. |
| RE-MEDY | Oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. |
|
SAGE |
A prospective, randomized, double-blind, multi-center study comparing the effects of aggressive lipid lowering with moderate lipid lowering on the reduction of the total duration of myocardial ischemia in the elderly as measured by holter monitoring by comparing the maximal doses of two statins: study assessing goals in the elderly. |
| SATURN | Rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured IVUS in patietns with CAD. |
| SAVOR-TIMI 54 | A multicentre, randomized, double-blind, placebo-controlled phase IV trial to evaluate the effect of saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with type 2 diabetes. |
SIGNIFY |
Effects of ivabradine in patients with stable CAD without clinical heart failure. A randomized double-blind placebo controlled study. |
|
SISA
|
Comparing balloon angioplasty versus stenting with the stent from medtronic in single de-novo lesions. |
| SNAPIST III | A phase I/II safety trial of intracoronary administration of systemic nanoparticle paclitaxel (ABI-007) for the prevention of in-stent restenosis. |
| SOLID TIMI 52 |
Clinical outcomes study of darapladib vs placebo in patients following ACS comparing incidence of major adverse cardiovascular events. |
| SOX | The SOX trial: compression stockings to prevent post-thrombotic syndrome. |
| SPIRE 1 and SPIRE 2 | Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of bococizumab (PF-04950615), in reducing the occurence of major cardiovascular events in high risk subjects. |
|
SYMPHONY |
Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes. |
|
SYNERGY |
Prospective, randomized, open-label, multicenter study in high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (ACS), including unstable angina and non-ST-segment elevation myocardial infarction, managed with an intended, early invasive treatment strategy. |
| STRADIVARIUS | Rimonabant 20mg od, for inhibition of atherosclerosis progression assessed by IVUS (intravascular ultrasound) in overweight patients with clustering risk factors. |
T89-07-CAESA |
Phase III trial to confirm the anti-anginal effect of T89 in patients with stable angina. |
|
TEDISAMIL |
Tedisamil in patients with chronic stable angina pectoris remaining symptomatic despite antianginal treatment including maximally tolerated diltiazem SR. |
|
TEDISIMAL |
The antianginal and antiischemic effects of tedisimal dihydrocholride in patients with documented coronary artery disease. |
|
TENAX-XR |
This study is a prospective, multicenter, consecutive, non-randomized, registry to evaluate the safety and efficacy of the Tenax-XRComplete stent in the treatment of a single de novo lesion in a native coronary artery. |
| THEMIS | A multinational, randomized, double-blind, placebo-controlled trial to evaluate the effect of ticagrelor 90 mg twice daily on the incidence of cardiovascular death, mycoardial infarction or stroke in patients with type 2 diabetes mellitus. |
|
TIMI 11B |
The effectiveness and safety of subcutaneous enoxaparin compared to intravenous unfractionated heparin for patients presenting with unstable angina or non-Q wave MI. |
| TOTAL | A randomized trial of routine aspiration thrombectomy with PCI versus PCI alone in patients with STEMI undergoing primary PCI. |
| TRUE-AHF |
Phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ularitide (Urodilatin) intravenous infusion in patients suffering from acute decompensated heart failure. |
| TRA-CER | SCH 530348 in addition to standard of care for patients admitted with ACS. |
| TREAT | Administration of ticagrelor in patients with ST elevation myocardial infarction treated with pharmacological thrombolysis. A ranodmozed, phase 3, non inferiority clincial trial to explore the safety and efficacy of ticagrelor compared to clopidogrel in patients with acute myocardial infarction with ST segment elevation treated with pharmacological thrombolysis. |
 |
 |
©Victoria Heart Institute Foundation
"Yesterday's research is tomorrow's best practice... Today's research leads to tomorrow's breakthroughs."